IL2-inducible T-cell kinase (ITK), a member of the Tec family tyrosine kinases, is the predominant Tec kinase in T cells and natural killer (NK) cells mediating T cell receptor (TCR) and Fc receptor (Fc R) initiated signal transduction. ITK deficiency results in impaired T and NK cell functions, leading to various disorders including malignancies, inflammation, and autoimmune diseases. In this mini-review, the role of ITK in T cell signaling and the development of small molecule inhibitors of ITK for the treatment of T-cell related disorders is examined.
Introduction
The Tec (tyrosine kinase expressed in hepatocellular carcinoma) family tyrosine kinases play important roles in mediating intracellular signaling in hematopoietic cells [1] . They consist of five members: Tec, Bruton's tyrosine kinase (BTK), IL2-inducible T-cell kinase (ITK, also known as EMT or TSK), resting lymphocyte kinase (RLK, also known as TXK) and bone marrow-expressed kinase (BMX, also known as ETK). BTK is an essential regulator of B cell receptor (BCR)-initiated signaling pathways [2, 3] . Three Tec kinases including ITK, RLK and TEC are expressed in T lymphocytes. ITK is expressed at the highest level in naïve T cells and thymocytes, followed by RLK and then TEC [4] . Their expression levels possibly contribute to their relative importance in T cells. Itk -/-mice have profound defects in Tcell development and function; combined deletion of ITK and RLK worsens these defects [5] [6] [7] ; however, no major defects in T cells have been described in Tec -/-mice [8] . During CD4 + T cell differentiation, ITK is expressed in both T helper type 1 (Th1) and T helper type 2 (Th2) cells with an upregulated level in Th2 cells, while RLK is expressed only in Th1 cells but not in Th2 cells, suggesting a critical role of ITK in the differentiation and function of Th2 cells [9] . ITK has also been shown to be important for the development of invariant natural killer T (NKT) αβ cells and NKT-like γδ T cells besides conventional T-cells [10, 11] . In natural killer (NK) cells, ITK positively regulates Fc receptor (FcR) -induced granule release, calcium mobilization, and cytotoxicity but negatively regulates natural killer group 2, member D (NKG2D)-initiated signaling [12] . These studies implicate an essential role of ITK in T and NK cell development and function, and therefore developing small molecular inhibitors of ITK for treatment of T and NK cell related diseases would be attractive.
Domain structure of ITK
The ITK gene, discovered in 1992 [13, 14] , is chromosomally localized at 5q31-32 position in humans [15] . ITK protein is a 72 kDa kinase expressed in T cells, NK cells and mast cells, and it contains five distinct domains including pleckstrin homology (PH), Tec homology (TH), Src homology 3 (SH3), Src homology 2 (SH2) and Src homology 1 (SH1) (Figure 1 ) [16, 17] . The PH domain is at the amino terminal of ITK and helps the protein to bind phosphorylated lipids on the membrane [18, 19] . The TH domain exhibits the familial recognition of ITK and contains a proline rich region (PRR) which is necessary for binding the SH3 domain [20, 21] . 
ITK-mediated TCR signaling pathways
ITK is a critical mediator of T cell receptor (TCR) signaling ( Figure 2 Activated ITK autophosphorylates Y180 in its SH3 domain and phosphorylates its downstream target PLCγ1. Activated PLCγ1 hydrolyzes PIP2 to produce inositol-3-phosphate (IP3) and diacylglycerol (DAG). IP3 binds to receptors on intracellular organelles and cause Ca 2+ release from the intracellular store, leading to sustained Ca 2+ influx and downstream activation of transcription factors including NFAT. DAG activates two signal pathways. One is mitogen activated protein kinase (MAPK) pathway which leads to the activation of extracellular signal regulated kinase (ERK) and the other one is Protein Kinase C (PKC). pathway which activates nuclear factor-kappaB (NF-қB) and c-Jun amino-terminal kinase (JNK). 
ITK and T cell disorders
Due to the critical role of ITK in T cell development and differentiation, disregulated ITK causes T cell related disorders. [61, 62] , which may also be related to impaired cytotoxic CD8 + T cell response. Human immunodeficiency virus (HIV) is a retrovirus causing acquired immunodeficiency syndrome (AIDS). ITK has been shown to be an important factor in regulating the infection and replication of HIV [63] . Critical activators of HIV transcription including NFAT, NFқB and activator protein 1 (AP-1) are regulated by ITK [64] . In addition, the assembly and release of HIV viral particles is influenced by ITK via its regulation on actin cytoskeleton rearrangement [65] [66] [67] .
Allergy and hypersensitivity

Autoimmune diseases
Autoimmune diseases are caused by the activation of self-reactive T cells resulting in impaired organ function. ITK positively regulates Th17 cells which mediate autoimmune disorders including experimental autoimmune encephalomyelitis (EAE) [68, 69] .
As a downstream mediator of the B7-CD28 costimulatory pathway, ITK also plays an important role in controlling the migration of auto-reactive T cells [70] .
T cell malignancies
ITK has been shown to be up-regulated and aberrantly activated in T-cell malignancies [71, 72] , and its downstream targets including NFAT, NFқB and MAPK are involved in the pathogenesis of T-cell malignancies [73] . Targeting the ITKdependent IL-2 receptor (CD25) signaling pathway in T-cell lymphomas / leukemias with anti-CD25 monoclonal antibodies has shown promising efficiency [74] . These results indicate that ITK is a potential therapeutic target for T cell malignancies.
Recently, a chromosomal translocation between Itk and spleen tyrosine kinase (Syk) leading to T-cell lymphoma was identified [75] [76] [77] . This translocation fuses the PH and TH domain from ITK to the SYK kinase The activation of ITK-SYK fusion protein is dependent on PI3k signaling [78] , suggesting that PI3K inhibitors may be effective in treating ITK-SYK initiated T-cell lymphoma [79, 80] . 
ITK inhibitors
Benzimidazole based ITK inhibitors
The benzimidazole series of compound 1 was identified by high throughput screening [84] . It is an ATP competitive and has an IC 50 value of 12 nM in the ITK enzyme assay.
Further modifications improved the selectivity, potency and drug-like properties including stability and oral administration. Compound 10n and 10o inhibited IL-2 production with an IC 50 of 240 nM and 690 nM, respectively, in a human whole blood assay. Oral administration of compound 10n inhibited the production of IL-2 and IL-4 in a mouse model of T cell activation induced by anti-CD3 [85] .
Aminopyrimidine based ITK inhibitors
Compound 44 is a potent small molecule inhibitor of ITK identified by high-throughput screening of a library containing 468,462 compounds [58] . It has an IC 50 of 65 nM in inhibiting ITK kinase activity. Compound 44 inhibited the secretion of IL-2 and IFN-γ and the proliferation of activated T cells. In two models of inflammatory skin diseases, compound 44 significantly reduced skin inflammation. 6.4 3-aminopyride-2-ones based ITK inhibitors This is a new series of ITK inhibitors identified by structure-based design, starting from 3-aminopyride-2-ones, a fragment designed de novo [86] . Among various derivatives, the compound 7v represented the best ITK inhibitor with good potency and selectivity.
Indolylndazole based ITK inhibitors ITK inhibitor 11o was identified based on indolylndazole libraries [87] . It had enzymatic activity at 11 nM and cellular activity at 20 nM. In an anti-CD3-induced IL-2 mouse model, intravenous or oral administration of 11o (10mg/kg) inhibited IL-2 secretion, and this drug was well tolerated without obvious side effects.
5H)-one, was developed through screening a library comprising 9600 compounds, followed by molecular modeling and analysis of SAR [88] . It showed the highest inhibition toward ITK with an IC 50 of 100 nM, followed by BTK with an IC 50 of 400 nM. CTA056 treatment in T cells inhibited the phosphorylation of ITK and its downstream targets including PLCγ1 and reduced the secretion of IL-2 and IFN-γ. CTA056 selectively targeted malignant T cells expressing ITK, including acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. In a xenograft model of T cell leukemia, CTA056 treatment (5 mg/kg, twice a week, intratumoral injection) prevented tumor growth.
ITK inhibitors targeting cysteine-442 in the ATP pocket
Ibrutinib is an irreversible inhibitor of BTK and ITK [89, 90] . It binds to cysteine-481 residue in BTK or cysteine-442 residue in ITK and inhibits downstream activation of BCR or TCR, respectively. After TCR stimulation in primary CD4 + T cells and Jurkat T cells, Ibrutinib inhibited activation of PLCγ1, NFAT, JunB and IKBα which are ITK downstream targets [89] . Interestingly, ibrutinib specifically inhibited Th2 T cell activation and Th2-type cytokine release and provided a selective advantage to Th1 and CD8 + T cells which express RLK beside ITK.
The inhibitory effect of ibrunitib on ITK was further validated in primary CLL samples and several murine models of CLL, parasitic infection (Leishmania major) and infectious disease (Listeria monocytogenes) [89] . Ibrutinib has shown significant clinical activity in the treatment of mantel cell lymphoma (MCL) and CLL [91] [92] [93] , and been approved by the U.S. Food and Drug Administration (FDA) for the treatment of these two malignancies.
Compound 12 is another irreversible ITK inhibitor targeting Cysteine-442 in the ATP pocket [94] . In activated human peripheral blood mononucleated cells (PBMCs), compound 12 had the most potency at inhibiting IL-12, followed by IFNγ, IL-13 and IL-17. The inhibition of T cell activation by compound 12 was demonstrated in a rat model by inhaled delivery of this drug. The inhibitory effect of compound 12 on Th1, Th2 and Th17 T cells suggests that it might also inhibit RLK, which needs verification by further study.
Other ITK inhibitors
ITK inhibitors based on pyrazolyl-indole [95] or thienopyrazole [33] were described in previous studies. Rosmarinic acid, a natural compound, was also shown to inhibit activation of ITK, PLCγ1, NFAT and Ca 2+ mobilization [35] . Instead of targeting the ATP site in ITK, inhibitors targeting ITK allosteric sites were discovered and characterized [96] .
Conclusion
Intensive studies have demonstrated the essential role of ITK in T cell development and differentiation, implicating ITK as a potent therapeutic target in various diseases including Th2 cell related immunodeficiency and inflammation.
The success of ibrutinib, a BTK/ITK-targeting inhibitor, in the treatment of B-cell leukemia and lymphoma encourages the development of such targeted therapy in T-cell related diseases. Though a number of ITK inhibitors have been discovered, most of them are still in their early stages of development and more effort is needed before their application in clinic. In addition, due to a compensatory role of RLK to ITK in Th1 T cells, development of dual inhibitors targeting both ITK and RLK will be important. 
